RAB5A and breast cancer: T-DM1 is currently approved only for advanced HER2-positive breast cancer previously treated with trastuzumab, but a defined RAB5A threshold-biomarker holds promise also for patient stratification at earlier stages of this disease29, in addition to other indications, such as gastric cancer23.